Stephen F. Mahoney insider trades
Open-market stock purchases and sales by Stephen F. Mahoney, President and CEO at Viridian Therapeutics, Inc.\DE, from SEC Form 4 filings since Feb 9, 2018.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -33%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Mar 3, 2026 | VRDN Viridian Therapeutics, Inc.\DE | Sold (not open market) | $224K |
| Mar 3, 2026 | VRDN Viridian Therapeutics, Inc.\DE | Bought (not open market) | — |
| Mar 3, 2026 | VRDN Viridian Therapeutics, Inc.\DE | Sold (not open market) | $224K |
| Mar 2, 2026 | VRDN Viridian Therapeutics, Inc.\DE | Bought (not open market) | — |
| Mar 2, 2026 | VRDN Viridian Therapeutics, Inc.\DE | Bought (not open market) | — |